Department of Radiation Oncology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lung Cancer. 2018 Apr;118:20-26. doi: 10.1016/j.lungcan.2018.01.021. Epub 2018 Jan 31.
Contrary to prevailing notions of uniform efficacy regarding stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC), a recent report has indicated increased risk of local failure for squamous cell carcinoma (SCC). As those data have not been corroborated by other studies, we performed a multi-institutional analysis to evaluate the influence of histology on post-SBRT outcomes.
Records from 152 consecutive patients who received SBRT for primary early-stage NSCLC at two academic medical centers were retrospectively assessed. Primary comparison was between SCC and adenocarcinoma. Patient outcomes including actuarial recurrences and overall survival were calculated using the Kaplan-Meier method. Univariable and multivariable logistic regression analyses addressed associated factors.
At a median follow-up of 44 months, patients with SCC had an increased risk of local, (hazard ratio (HR) (95% confidence interval (CI)): 1.69 (1.05-2.73), p = 0.032), regional (HR (95% CI): 2.03 (1.24-3.33), p = 0.005), and distant failure (HR (95% CI): 1.71 (1.06-2.77), p = 0.036). Median times to local (32 m vs 50m, p = 0.023), regional (26 m vs 50 m, p = 0.011), and distant (26 m vs 50 m, p = 0.024) failure were all significantly reduced in SCC histology. SCC histology was also independently associated with an increased risk for death (HR: 1.80 (1.10-2.94), p = 0.019) and had a 5-yr overall survival of 26%, versus 41% for adenocarcinoma (p = 0.016).
This multi-institutional analysis corroborates that SCC histology is independently predictive for local, regional, and distant recurrence and worse overall survival. Future data are needed to determine if treatment paradigms should differ by histology for early stage NSCLC.
与立体定向体放射治疗(SBRT)治疗早期非小细胞肺癌(NSCLC)疗效一致的普遍观念相反,最近的一份报告表明,鳞状细胞癌(SCC)局部失败的风险增加。由于这些数据尚未得到其他研究的证实,我们进行了一项多机构分析,以评估组织学对 SBRT 后结果的影响。
回顾性评估了在两个学术医疗中心接受 SBRT 治疗原发性早期 NSCLC 的 152 例连续患者的记录。主要比较是 SCC 和腺癌。使用 Kaplan-Meier 方法计算患者的累积复发和总生存率。单变量和多变量逻辑回归分析确定相关因素。
在中位数为 44 个月的随访中,SCC 患者局部(危险比(HR)(95%置信区间(CI)):1.69(1.05-2.73),p=0.032)、区域(HR(95% CI):2.03(1.24-3.33),p=0.005)和远处失败(HR(95% CI):1.71(1.06-2.77),p=0.036)的风险增加。SCC 组织学的局部(32 个月 vs 50 个月,p=0.023)、区域(26 个月 vs 50 个月,p=0.011)和远处(26 个月 vs 50 个月,p=0.024)失败时间中位数均显著缩短。SCC 组织学与死亡风险增加(HR:1.80(1.10-2.94),p=0.019)独立相关,5 年总生存率为 26%,而腺癌为 41%(p=0.016)。
这项多机构分析证实,SCC 组织学是局部、区域和远处复发以及总体生存率降低的独立预测因素。需要进一步的数据来确定早期 NSCLC 的治疗方案是否应根据组织学进行区分。